File:State of Medicon Valley 2016 patent 20161107 (30190715584).jpg

In 2012, Medicon Valley filed more than double as many patent applications to the EPO within medical or veterinary science than the Stockholm-Uppsala region (by priority date). Leading life science companies as Novozymes and Novo Nordisk are among the 25 top applicants to EPO – Novo Nordisk in the categories medical technology, biotechnology and pharmaceuticals, and Novozymes in biotechnology. The only life science company with activity in Sweden on the top 25 list is Astra Zeneca, but its presence owes to research activity in other countries than Sweden.

State of Medicon Valley 2016 An Analysis of Life Science in Greater Copenhagen Commissioned and published by: Medicon Valley Alliance. This analysis has been prepared by Øresundsinstituttet and was written by Britt Andresen, Johan Wessman, Jenny Andersson, Anna Palmehag and Thea Wiborg. Layout: Jenny Andersson. November 2016

Link to the full report <a href="http://www.oresundsinstituttet.org/state-of-medicon-valley-2016-ny-analys-fran-oresundsinstituttet/" rel="nofollow">www.oresundsinstituttet.org/state-of-medicon-valley-2016-...</a>

Medicine Valley Alliance <a href="http://www.mva.org" rel="nofollow">www.mva.org</a>

Øresundsinstituttet <a href="http://www.oresundsinstituttet.org" rel="nofollow">www.oresundsinstituttet.org</a>

Copyright: Øresundsinstituttet, (CC BY 3.0) Creative Commons 3.0 Unported-licens.

This figure presents data from OECD and EPO for patent applications to the European Patent Office (EPO) distributed by priority date and publication data. Normally, a patent application to EPO is preceded by an application to the national patent office. The filing date for the application to the national patent office is the priority date for the subsequent application to EPO. The publishing date for a patent application to EPO is usually 18 months after the priority date. Patent information from USPTO is rather old at the time of publishing, and for that reason it has been chosen primarily to present data for EPO, even though the interest in patent applications at USPTO has grown as a consequence of the growth of the American medical market. The international patent classification (IPC) has been used in order to isolate life science patent applications from other categories. The Danish Patent and Trademark Office identified the relevant IPC categories for life science, which have been extracted from the OECD database. The figures presented use the applicant’s country and municipality of residence to distribute the patent applications geographically. Source for the regional distribution of patent application is EUROSTAT. EUROSTAT does not present the figures on detailed IPC categories, therefore, only figures for medical or veterinary science is presented.